Suppliers and packagers for miglustat

miglustat

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Ani Pharms	MIGLUSTAT	miglustat	CAPSULE;ORAL	208342	ANDA	ANI Pharmaceuticals, Inc.	43975-310-83	6 BLISTER PACK in 1 CARTON (43975-310-83) / 15 CAPSULE in 1 BLISTER PACK (43975-310-08)	2018-04-17
Navinta Llc	MIGLUSTAT	miglustat	CAPSULE;ORAL	219111	ANDA	Navinta LLC	68475-204-02	6 BLISTER PACK in 1 CARTON (68475-204-02) / 15 CAPSULE in 1 BLISTER PACK (68475-204-01)	2025-05-07
Navinta Llc	MIGLUSTAT	miglustat	CAPSULE;ORAL	219111	ANDA	Zydus Pharmaceuticals USA Inc.	70710-2039-8	6 BLISTER PACK in 1 CARTON (70710-2039-8) / 15 CAPSULE in 1 BLISTER PACK (70710-2039-4)	2025-04-01

Suppliers for the Pharmaceutical Drug: Miglustat

Last updated: July 27, 2025

Introduction

Miglustat, marketed under brand names such as Zavesca, is a small-molecule therapeutic primarily used to treat certain lysosomal storage disorders, notably Gaucher type 1 and Niemann-Pick disease type C. Its mechanism involves the inhibition of glucosylceramide synthase, thereby reducing glycosphingolipid accumulation in affected cells. Due to its specialized application, the supply chain of Miglustat is characterized by a limited number of key manufacturers, often under strict regulatory oversight. Recognizing the current landscape of suppliers is vital for pharmaceutical companies, healthcare providers, and stakeholders aiming to ensure continuous access and supply stability.

Manufacturers and Key Suppliers of Miglustat

Global Production Overview

Miglustat is predominantly manufactured by a select group of pharmaceutical companies, possessing specialized synthesis capabilities and regulatory approvals. The landscape is highly concentrated due to the complex manufacturing processes and stringent quality standards governing specialty drugs.

Nihon Pharmaceutical Co., Ltd.

One of the original developers and licensors of Miglustat, Nihon Pharmaceutical, holds substantial manufacturing rights, particularly in Japan and parts of Asia. Their facilities are GMP-certified, adhering to international standards necessary for pharmaceutical production. Nihon’s role is critical in regions where local regulatory approval is aligned with their manufacturing capabilities.

Actelion Pharmaceuticals (Janssen Pharmaceutical Companies)

Janssen, a subsidiary of Johnson & Johnson, acquired Actelion in 2017, inheriting the rights to Zavesca (Miglustat). Actelion pioneered the development of Miglustat, with Janssen maintaining its global manufacturing and distribution. The company operates multiple production sites across Europe and North America, ensuring broad access to the drug.

Other Notable Suppliers

While Nihon and Janssen dominate the manufacturing landscape, other companies have been involved in contract manufacturing or licensing arrangements:

• Mundipharma International: Has engaged in distribution and supply arrangements in select markets, mainly acting as an importer or distributor rather than a direct manufacturer.
• Contract Manufacturing Organizations (CMOs): Several CMOs globally possess the capacity to produce Miglustat under licensing agreements with patentholders or brand owners, although these are less publicly documented due to proprietary confidentiality.

Supply Chain Challenges

The specialized nature of Miglustat production, including its complex synthesis pathways, regulatory hurdles, and limited market size, constrains the number of suppliers. Additionally, patent protections and exclusivity rights can limit licensing agreements to specific manufacturers, further narrowing the supply base.

Regional Suppliers and Market Dynamics

North America

In the United States and Canada, Janssen has exclusive rights to distribute Miglustat. The company’s production facilities in Europe and North America ensure supply continuity, provided regulatory compliance is maintained.

Europe and Asia

European markets often rely on Janssen’s manufacturing sites. In Japan and other parts of Asia, Nihon Pharmaceutical plays a pivotal role. Regulatory approvals in these regions are aligned with local manufacturing, making these suppliers primary sources.

Emerging Markets

Emerging markets face additional challenges due to import restrictions and limited local manufacturing. Some regional distributors source Miglustat through licensing agreements with primary suppliers, but supply gaps can occur without diversified manufacturing pathways.

Regulatory and Patent Considerations Impacting Supply

The patent status of Miglustat varies internationally, with exclusivity rights influencing manufacturing and licensing. Once patents expire, generic manufacturers can enter the market, broadening the supplier base, and potentially reducing costs. As of now, patent expirations have yet to significantly impact the global supply chain, maintaining reliance on the original patentholders and licensees.

Future Outlook and Potential Suppliers

Biosimilar and Generic Developers

The impending expiration of patent protections for Miglustat would allow generic pharmaceutical companies to develop biosimilar or generic versions. Companies such as Teva Pharmaceutical Industries and Mylan (now part of Viatris) have shown interest in entering markets for similar glycosylation inhibitors. Regulatory pathways for biosimilars could lead to increased competition, expanding the supplier landscape.

Contract Manufacturing Expansion

Given the increasing demand for orphan drugs, Contract Manufacturing Organizations (CMOs) are expected to expand capacity for Miglustat production, especially if patent protections lapse or licensing agreements are negotiated post-expiry. Strategic partnerships could diversify the supply chain and enhance resilience.

Supply Chain Risks and Mitigation Strategies

Limited supplier options elevate risks of shortages due to manufacturing disruptions, regulatory delays, or geopolitical issues. Companies should consider supply chain diversification, establishing relationships with multiple licensed manufacturers, and monitoring patent and regulatory developments to mitigate potential disruptions.

Key Takeaways

• Primary Suppliers: Nihon Pharmaceutical and Janssen Pharmaceuticals are the main global manufacturers of Miglustat, holding licenses and manufacturing rights that ensure supply in key regions.
• Market Concentration: The supply chain is highly concentrated, with limited players due to complex synthesis, regulatory hurdles, and patent protections.
• Post-Patent Scenarios: Expiry of patents may enable generic manufacturers to enter the market, broadening the supplier base and potentially reducing costs.
• Supply Chain Risks: Concentration increases vulnerability to disruptions; diversification and proactive licensing strategies are essential.
• Future Developments: Emerging biosimilars and biosimilar manufacturers could alter the supply landscape, enhancing competition and supply security.

FAQs

1. Who are the main global producers of Miglustat?
Janssen Pharmaceuticals (owned by Johnson & Johnson) and Nihon Pharmaceutical Co., Ltd. are the primary manufacturers, with Janssen holding the rights for many markets worldwide.

2. Are there generic versions of Miglustat available?
Currently, generic versions are not widely available due to patent protections. The expiration of patents could pave the way for generics, which is anticipated to increase supply options.

3. How does patent expiration influence the supply of Miglustat?
Patent expiration allows generic manufacturers to produce biosimilar versions, increasing competition, diversifying suppliers, and typically lowering prices.

4. What factors could threaten the stability of Miglustat supply?
Regulatory delays, manufacturing disruptions, geopolitical issues, and patent litigations pose risks to supply continuity.

5. Is there a risk of supply shortages for patients requiring Miglustat?
Yes, due to the limited number of manufacturers and complex supply chains. Strategic partnerships and market diversification are vital to mitigate this risk.

References

1. [1] Johnson & Johnson. "Zavesca (Miglustat) Prescribing Information," 2023.
2. [2] Nihon Pharmaceutical Co., Ltd. Official Website. "Our Manufacturing Capabilities," 2023.
3. [3] European Medicines Agency. "Miglustat Authorizations," 2022.
4. [4] U.S. Food & Drug Administration. "Miglustat Approval and Market Status," 2023.
5. [5] Pharma & Biotech Industry Reports. "Future Outlook for Specialty Drug Suppliers," 2023.